

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58465 A2

- (51) International Patent Classification⁷: A61K 35/74, L9P 1R1 (CA). HAN, Victor [CA/CA]; 132 Timber Crescent, London, Ontario N6K 2W2 (CA).
A61P 1/00
- (21) International Application Number: PCT/CA01/00157 (74) Agents: ZAHIL, Adrian et al.; McFadden, Fincham, Suite 606, 225 Metcalfe Street, Ottawa, Ontario K2P 1P9 (CA).
- (22) International Filing Date: 9 February 2001 (09.02.2001) (81) Designated States (national): AU, CA, MX.
- (25) Filing Language: English (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- (26) Publication Language: English
- (30) Priority Data: 60/181,702 10 February 2000 (10.02.2000) US Published:
— without international search report and to be republished upon receipt of that report
- (71) Applicants and
(72) Inventors: REID, Gregor [CA/CA]; 71 Chesham Avenue, London, Ontario N6G 3V1 (CA). BRUCE, Andrew, W. [CA/CA]; 485 Sandford Road, R.R. #1, Uxbridge, Ontario
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/58465 A2

(54) Title: PROBIOTIC THERAPY FOR NEWBORNS

(57) Abstract: The invention relates to a probiotic microbes including but not limited to *Lactobacillus* species and *Bifidobacteria* species, and their compositions and methods of employing said compositions for treating and preventing intestinal and other infections which originate from the intestine, newborn infants. The invention also relates to the ability of probiotic organisms, either in viable or nonviable state, or their by-products, to interfere with pathogenic infection through short and long term colonization of the intestine, inhibition of growth of the pathogens, and assisting the host to fight off the infecting organisms.

PROBIOTIC THERAPY FOR NEWBORNSFIELD OF THE INVENTION

5 The present invention relates to compositions
and methods employing probiotic microbial compositions
for treating and preventing intestinal and other
infections which originate from the intestine, in
newborn infants.

BACKGROUND OF THE INVENTION

10 Each year, intestinal infections kill more
people in the world than any other disease. Many of the
victims of intestinal infections are children in Third
World Countries. The causative agents are mainly bacteria
15 and viruses. Presuming the availability and access to
antibiotics and other chemotherapeutic treatments (and
many in the Third World do not have such access), these
intestinal and urogenital infections are usually not
fatal. However, increased antibiotic resistance and poor
20 nutrition and hygiene result in continually elevated
morbidity and mortality rates.

 Once a child is born, intestinal infections are
common (21-37 million diarrheal disease episodes in 16.5
million US children each year) and death can occur
25 (around 200 annually in US and Canada). Necrotizing
enterocolitis, for example, is one of the most
devastating diseases that a preterm infant faces during
its efforts to continue its fragile existence within a
neonatal intensive care unit (NICU). The incidence of
30 necrotizing enterocolitis, ranges from 10-25% of preterm
infants (about 1,500g in weight) admitted to the NICU,
and may involve approximately one third to one half of

all very low birth weight infants. Of those, approximately half will require surgery. The mortality ranges from 25-30%, and of those who survive, around 25% experience long term sequelae. In some cases, the sequelae result from multi-system organ failure which has damaged the lungs or other organs.

The infecting organisms are broad in their range, and include *Clostridium*, *Escherichia*, *Klebsiella*, *Salmonella*, *Shigella*, *Campylobacter*, *Pseudomonas*, *Streptococcus*, *Enterococcus*, *Staphylococcus*, coagulase-negative staphylococci, other Gram positive cocci, and other species including yeasts, viruses and protozoa.

A critical factor in protecting infants appears to be the formation of a protective intestinal flora. It is known that a flora high in protective bacteria (such as lactobacilli and bifidobacteria, believed to be transferred from the breast feeding mother), is critical to fighting off harmful organisms. However, the protective flora is not well established in these premature infants and by supplementing the flora with exogenous normal flora (either true probiotic organisms or the mother's own normal flora members) the risk of infection will be significantly reduced. Moreover, when infection ensues, treatment with probiotics will reduce the subsequent severity and longevity of the illness.

In recent years, Gregor Reid, Ph.D. and Andrew Bruce, M.D. have investigated the use of *Lactobacillus* to prevent and treat urogenital infections (Reid et al. (1998) Int. Dairy J. 8:555-562). This has included the development of probiotics which are ingested and which colonize and pass through the intestine to the vagina. These organisms have been shown to inhibit the growth and

adhesion of pathogens and coaggregate to form a balanced normal flora which protects the host against infection.

The present invention now takes into account an infectious state not previously investigated for the application of probiotics, namely intestinal infections, particularly necrotizing enterocolitis, in premature newborn infants. While the importance of the ability of probiotic organisms to adhere and produce substances and conditions inhibitory to growth and adherence by harmful pathogens has been recognized, it has only now been appreciated, in accordance with the present invention that probiotics are primary colonizers i.e. the first microbes to reach the intestine and colonize the intestines of newborns.

The nature of the probiotic organisms which are used in this patient population is also important. These must adhere to intestinal cells, grow and survive and provide a health benefit to the host. Examples of appropriate strains are *Lactobacillus rhamnosus* GR-1, *Lactobacillus fermentum* RC-14 and *Bifidobacterium*. GR-1 and RC-14 have been demonstrated to produce substance antagonistic to various enteric pathogens (unpublished data and Velraeds et al. (1998) J. Med. Microbiol. 49:790-794). *Bifidobacteria* have been shown to effectively treat intestinal infections in Chernobyl patients in Russia, where the intestine has been damaged by exposure to radiation (unpublished data). There is also evidence to show that probiotics prevent and reduce the duration of diarrhea in older children whose intestinal flora has already been established. However, none of these studies have investigated newborns, nor

addressed a situation where the newborn's intestine is undercolonized.

In studies of acute diarrhea (bacterial and rotaviral) in children 6 to 36 months of age, a *Lactobacillus reuteri* probiotic was given at 10^e10 and 10^e11 colony-forming units daily for 5 days and found to significantly reduce the duration of watery diarrhea compared with placebo (Shornikova et al. J. Pediatr. Gastroenterol. Nutr. 1997, 24: 399-404; and Shornikova et al. Pediatr. Infect. Dis. 1997, 16: 1103-1107). These studies described the safe application of probiotics to treat infection. The difference between these studies and the present invention is that the babies that are effectively treated by the present invention are premature, underweight newborns, who do not have a normal established flora, and the enterocolitis which they acquire is of a more serious nature to the child's survival.

SUMMARY OF THE INVENTION

The present invention demonstrates specially selected probiotic organisms with antagonistic properties against intestinal pathogens, can colonize, treat and provide protection against intestinal infection in newborns.

The present invention provides methods and compositions for the treatment and inhibition of intestinal infection caused by pathogenic organisms. Oral, rectal or intravenous administration of *Lactobacillus* and other probiotic compounds in a pharmaceutically acceptable carrier, such as milk or

portions thereof provide a safe and effective means for colonizing the intestine, and treating, inhibiting or reducing the occurrence of intestinal infections in newborns.

5 In the practice of the compositions and methods of the present invention, the *Lactobacillus* may be administered as viable whole cells. The *Lactobacillus* species may be aerobically grown or microaerophillically grown and selected from *L. rhamnosus*, *L. acidophilus*, *L.*
10 *crispatus*, *L. fermentum*, *L. plantarum*, *L. casei*, *L. paracasei*, *L. jensenii*, *L. gasseri*, *L. cellobiosis*, *L. brevis*, *L. delbrueckii*, *L. rogosae* and *L. bifidum*.

In one embodiment the present invention provides a newborn infant composition having one or more
15 probiotic organisms such as lactobacillus and bifidobacteria.

In another embodiment of the present invention a newborn infant composition is provided having one or
20 more probiotic organisms which are isolated from the intestinal flora of the newborn infant's mother.

In still another embodiment of the present invention a method is provided for colonizing the gastrointestinal flora in newborns comprising administering a therapeutically effective amount of at
25 least one probiotic organism and a pharmaceutically acceptable carrier. In a further embodiment of the method a therapeutically effective amount of a second probiotic organism is administered. *Lactobacillus* is the preferred probiotic organism. Bifidobacteria is the
30 preferred second probiotic organism. The Bifidobacterium is preferably selected from the group consisting of *B.*

bifidum, *B. breve*, *B. adolescentis*, *E. infantis*, *B. pseudolongum*, *B. angulatum*, *E. catenulatum* or *B. longum*.

In yet another embodiment, the present invention describes a method of treating an infection in a newborn comprising administering a therapeutically effective amount of pharmaceutical composition comprising one or more isolated probiotic organisms and a pharmaceutically acceptable carrier to an infant in need of such treatment.

In still yet another embodiment, the present invention provides a method of enhancing protective gastrointestinal flora in newborns comprising administering a therapeutically effective amount of at least one probiotic organism and a pharmaceutically acceptable carrier.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compositions and methods for the prevention and treatment of intestinal and other infections which originate from the intestine, in newborn infants by use of probiotic microbes or their by-products.

Premature infants weighing about 1500g have little protective pioneer or primary-colonizing normal flora as a consequence of their neonatal low birth weight and underdeveloped intestinal epithelium. As a consequence, these newborns have an increased incidence of intestinal infections. In addition, premature infants typically receive antibiotic therapy and are prone to antibiotic-induced diarrhea, for example. Therefore, premature infants receive intravenous nutrition which disrupts or inhibits the formation of normal protective

intestinal flora. The infections which ensue are commonly treated with antibiotics which further disrupt congenitally fragile flora.

5 While not wishing to be bound by a particular mechanism, the probiotic organisms of the present invention produce a primary barrier population which adheres to and protects the intestinal flora of the newborn and reduces the risk of infection and disease.

10 The ingestion or instillation of the probiotic organism compositions of the present invention enhances the protective flora and also enhances the recipient's immune system to fight off potential infecting microbes

By "newborn" is meant an infant born at about 32 weeks, and weighing about 1500g. By "probiotic" is
15 meant an organism which has one or more of the following characteristics, an ability to: (i) adhere to cells; (ii) exclude or reduce pathogenic adherence; (iii) persist and multiply; (iv) produce acids, hydrogen peroxide and bacteriocin antagonistic to pathogen growth; (v) resist
20 vaginal microbicides including spermicides; (vi) be safe and therefore noninvasive, noncarcinogenic and nonpathogenic; and (vii) coaggregate and form a normal, balanced flora.

A preferred probiotic bacteria is one or more
25 species of lactobacillus and extracts or by-products thereof. The probiotic microbes are strains of lactobacilli and/or bifidobacteria conventionally derived from the mother of the newborn or an exogenous source. The probiotic microbes colonize the intestine, and have
30 properties antagonistic to pathogens which cause enterocolitis. Pathogens antagonized or otherwise substantially eradicated by the probiotic compositions of

the present invention are bacteria, protozoa, fungi and viruses which cause enterocolitis or related infections. The pathogens include but are not limited to *Clostridium*, *Escherichia*, *Klebsiella*, *Salmonella*, *Shigella*,
5 *Campylobacter*, *Pseudomonas*, *Streptococcus*, *Enterococcus*, *Staphylococcus*, coagulase-negative staphylococci, other Gram positive cocci, and other species including yeasts, viruses and protozoa.

In another embodiment of the present invention
10 the pathogen may be resistant to antibiotics, as is the case with multi-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). In these situations, the probiotics of the present invention are administered to the newborn to treat the infection and to
15 bind to the pathogens thereby reducing their infectivity. While not wishing to be bound by a particular mechanism, the probiotic organisms bind to and coaggregate with the pathogens thereby forming a biofilm. The biofilm functions to reduce the toxic effects of the pathogens to
20 the host, thereby inhibiting or preventing the infectious process.

The invention utilizes therapeutically effective amounts of one or more of the probiotic organisms, and/or their metabolic by-products, within
25 days, and preferably within about 72 hours, of the birth of the newborn. The composition is instilled orally or rectally in the form of freeze dried preparation, paste, liquid, gel or other delivery mechanism including a rectal suppository. The probiotic organisms may also be
30 administered intravenously, parenterally or intraperitoneally. Dispersions can also be prepared, for

example, in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils.

5 The probiotic bacteria of the present invention are used to counteract bacteria and viruses in the intestinal tracts. Other orifices and surfaces are colonized naturally by organisms without any known detrimental affect to the host. These include the nasopharynx and skin. In accordance with the present invention probiotic agents are applied to sites, such as
10 the nasopharynx and skin. In these cases, the probiotic organisms of choice may not be lactobacilli or bifidobacteria, but may be other aerobes or anaerobes.

In another embodiment the composition is applied in suspension, as a topical application to
15 orifices, such as wounds, the oral cavity and nasopharynx of a newborn. Administration to the oral cavity is by mouth or by application of a medical device (inserted into the infants' mouth) onto which viable or non-viable organisms or their by-products are coated.

20 By "therapeutically effective amount" as used herein is meant an amount high enough to significantly positively modify the condition to be treated but low enough to avoid serious side effects (at reasonable benefit/risk ratio) within the scope of sound medical
25 judgment. The therapeutically effective amount will vary with the particular condition being treated, or the condition of the newborn and his/her physical condition, as well as the type of preparation being used.

30 In the practice of the method as hereinabove defined, the probiotic bacteria may be administered as viable whole cells. The *Lactobacillus* may be aerobically, anaerobically or microaerophilically grown, preferably

selected from the group consisting of *L. casei*, *L. rhamnosus*, *L. acidophilus*, *L. plantarum*, *L. fermentum*, *L. reuteri*, *L. jensenii*, *L. gasserii*, *L. cellobiosus*, *L. crispatus*, *L. brevis*, *L. salivarius*, *L. paracasei*, *L. delbrueckii*, *L. helveticus*, *L. collinoides*, *L. buchneri*, *L. rogosae*, and *L. bifidum*.

In a preferred aspect, the *Lactobacillus* is selected from the group consisting of *Lactobacillus casei* var *rhamnosus* (GR-1 (ATCC 55826), *L. casei* var *rhamnosus* GR-2 (ATCC 55915), *L. casei* var *rhamnosus* GR-3 (ATCC 55917), *L. casei* var *rhamnosus* GR-4 (ATCC 55916), *L. casei* var *rhamnosus* RC-9, *L. casei* var *rhamnosus* RC-17 (ATCC 55825), *L. casei* var *alactosus* RC-21, *L. casei* NRC 430, *L. casei* ATCC 7469, *L. casei* var *rhamnosus* 81, *L. casei* var *rhamnosus* 76, *L. casei* var *rhamnosus* 36W, *L. casei* var *rhamnosus* 36g, *L. casei* RC-65, *L. casei* RC-15, *L. casei* 558, *L. casei*, RC-21, *L. casei* 55, *L. casei* 8, *L. casei* 43, *L. plantarum* RC-12 (ATCC 55895), *L. acidophilus* RC-25, *L. plantarum* RC-19, *L. jensenii* RC-11 (ATCC 55901), *L. acidophilus* ATCC 4357, *L. acidophilus* 2099 B, *L. acidophilus* 2155C, *L. acidophilus* T-13, *L. acidophilus* 1807B, *L. acidophilus* RC-16, *L. acidophilus* RC-26, *L. acidophilus* RC-10, *L. acidophilus* RC-24, *L. acidophilus* RC-13, *L. acidophilus* RC-14, *L. acidophilus* RC-12, *L. acidophilus* RC-22, *L. acidophilus* 2099B, *L. acidophilus* 2155C, *L. acidophilus* T-13, *L. plantarum* ATCC 8014, *L. plantarum* UH 2153, *L. plantarum* 260, *L. plantarum* RC-20, *L. plantarum* 75, *L. plantarum* RC-6, *L. fermentum* A-60, *L. fermentum* B-54 (identical ribotype to RC-14) (ATCC 55920), *L. cellobiosus* RC-2, *L. crispatus* 1350B and *L. crispatus* 2142B. A most preferred *Lactobacillus* species is *L. fermentum* RC-14. Another

preferred lactobacillus species is *L. rhamnosus* GR-1.
Still another preferred lactobacillus species is *L.*
fermentum B-54.

5 The bifidobacteria may be anaerobically grown
and preferably selected from the group consisting of
Bifidobacterium adolescentis, *B. bifidum*, *B. infantis*, *B.*
pseudolongum, *B. angulatum*, *B. catenulatum* or *B. longum*.

10 The bifidobacteria and/or lactobacilli are
isolated from the newborn mother's intestine via a fecal
sample, then purified, grown anaerobically and
reimplanted into the newborn together with a
pharmaceutically acceptable carrier. It has been found in
accordance with the present invention that a composition
15 comprising about 10^3 /ml to about 10^9 /ml probiotic
organisms is suitable for treating and preventing
intestinal infections and/or enhancing protective flora
in newborns.

By "pharmaceutically-acceptable carrier" as
used herein is meant one or more compatible solid or
20 liquid filler diluents, or encapsulating substances. By
"compatible" as used herein is meant that the components
of the composition are capable of being comingled without
interacting in a manner which would substantially
decrease the pharmaceutical efficacy of the total
25 composition under ordinary use situations.

Some examples of substances which can serve as
pharmaceutical carriers are sugars, such as lactose,
glucose and sucrose; starches such as corn starch and
potato starch; cellulose and its derivatives such as
30 sodium carboxymethylcellulose, ethylcellulose and
cellulose acetates; powdered tragacanth; malt; gelatin;
talc; stearic acids; magnesium stearate; calcium sulfate;

vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, manitol, and polyethylene glycol; agar; alginic acids; 5 pyrogen-free water; isotonic saline; and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, 10 flavoring agents, lubricants, excipients, tabletting agents, stabilizers, anti-oxidants and preservatives, can also be present.

The pharmaceutically acceptable carrier may be in the form of milk or portions thereof including yogurt. 15 Skim milk, skim milk powder, non-milk or non-lactose containing products may also be employed. The skim milk powder is conventionally suspended in phosphate buffered saline (PBS), autoclaved or filtered to eradicate proteinaceous and living contaminants, then freeze dried 20 heat dried, vacuum dried, or lyophilized.

The invention will now be illustrated by means of the following non-limiting examples.

EXAMPLE 1

As soon as the baby is born, and is found to be premature or about 1,500g in weight, and once it is in a stable enough condition to receive fluids by mouth, a probiotic composition is administered once or more times (up to about five) daily for between 1 and about 140 to about 168 days (six months). The probiotics are preferably contained in a saline or milk suspension, if milk then preferably that of the mother's, in numbers approximately >1,000 per ml to 100,000,000 per ml. It is expected that 1 ml will be administered each time, but this will depend upon the estimated benefit/risk situation decided by the neonatologist. The ideal dosage will be sufficient to allow the probiotic organisms to colonize the newborn's intestine. The duration of treatment will extend for the duration of the child's stay in the NICU, or the time at which it is most susceptible to enterocolitis. One example of a dosage would be 1ml of a concentration of 100,000,000 per ml five times daily for one week to establish the organisms in the gut, then a maintenance dose of up to about 5ml at 1,000,000 per ml once daily for the remainder of stay in NICU or, if discharged but still susceptible to infection, for a further three months.

EXAMPLE 2

5 The second situation for application of the
probiotics would be a newborn who has left the hospital,
but who is deemed to be at risk of infections, perhaps
through immunosuppression, or other ailments, or who has
10 had antibiotic therapy and their normal gut flora has
been disrupted. The probiotic composition is taken once
daily (with or without the antibiotics) for periods
ranging from days to months, depending upon the degree of
10 susceptibility to infection.

EXAMPLE 3

Probiotic strains originating from the mother are utilized where it is recognized that newborn delivery is likely. A fecal sample is collected from the mother, and the most dominant lactobacilli and bifidobacteria present in the stool are isolated, purified and grown to sufficient numbers to allow implantation into the newborn. The organisms are suspended in either skim milk, or the mother's milk if available, then implanted as in examples 1 and 2. The strains are speciated and stored in glycerol vials in the freezer or as freeze dried vials.

EXAMPLE 4

5 If enterocolitis signs and symptoms appear or
an intestinal infection is suspected by a physician, or
laboratory diagnosis confirms infection is present,
probiotics compositions are administered to the infant by
oral or rectal delivery. This will occur more than once
per day, especially if the child is vomiting and has
diarrhea, (thereby making it difficult for administered
probiotics to stay in the stomach or intestine long
10 enough for them to colonize).

EXAMPLE 5

5 The probiotics herein described are
administered in combination with antibiotics given to
eradicate the offending pathogens in the gut, or given
for other purposes (e.g. for secondary lung infection).
In this example, the probiotic organisms selected for
such usage, are resistant to the antibiotics being
administered. This combination treatment permits the
normal barrier population of the intestine to be
10 strengthened at the same time that the harmful bacterial
count is depleted.

EXAMPLE 6

Bifidobacteria and/or lactobacilli are isolated from the newborn mother's intestine via a fecal sample as follows. A fecal sample is dispersed in saline and a
5 sample is diluted and plated onto agar which supports the preferred growth of the desired organisms, such as MRS agar or Rogosa's agar. Colonies of the most dominant lactobacilli or bifidobacteria then grow, and they are purified and conventionally tested by Gram stain and
10 biochemical and molecular typing methods to confirm their purity and speciation. The bacterium is then grown to produce large numbers, in a broth culture for two days under anaerobic conditions. The organisms are washed to remove excess broth, then stored in a freeze dried form
15 or in glycerol stock cultures in the -70°C freezer. Prior to re-inoculating into the newborn, the organisms are subcultured in broth, grown, washed and resuspended in suitable concentrations and a pharmaceutically acceptable carrier (such as skim milk or saline) then
20 administered to the newborn.

WHAT IS CLAIMED IS:

1. A newborn infant composition comprising one or more probiotic organisms and a pharmaceutically acceptable carrier.
- 5 2. The composition of Claim 1 wherein said probiotic organism is selected from the group consisting of a lactobacillus and bifidobacteria.
3. A newborn infant composition comprising one or more probiotic organisms isolated from the intestinal
10 flora of said infant's mother and a pharmaceutically acceptable carrier.
4. A method of treating an infection in a newborn comprising administering a therapeutically
15 effective amount of a pharmaceutical composition comprising one or more isolated probiotic organisms and a pharmaceutically acceptable carrier to an infant in need of such treatment.
5. The method of claim 4 wherein said probiotic is isolated exogenously.
- 20 6. The method of claim 4 wherein said probiotic is isolated from the intestinal flora of said newborn's mother.
7. The method of claim 4 wherein said probiotic is administered orally.
- 25 8. The method of claim 4 wherein said probiotic is administered rectally.
9. The method of claim 4 wherein said probiotic is administered intravenously.
- 30 10. The method of claim 4 wherein said probiotic is administered topically.
11. The method of claim 4 wherein said infection is intestinal.

12. The method of claim 11 wherein said intestinal infection is enterocolitis.

13. A method of colonizing gastrointestinal flora in newborns comprising administering a therapeutically effective amount of at least one probiotic organism and a pharmaceutically acceptable carrier.

14. The method of claim 13 further comprising the administration of a therapeutically effective amount of at least one second probiotic organism.

15. The method of claim 13 wherein said probiotic organism is a *Lactobacillus*.

16. The method of claim 14 wherein said second probiotic organism is a *Bifidobacterium*.

17. The method of claim 13 wherein said probiotic organism is selected from the group consisting of *L. rhamnosus*, *L. acidophilus*, *L. fermentum*, *L. casei*, *L. reuteri*, *L. crispatus*, *L. plantarum*, *L. paracasei*, *L. jensenii*, *L. gasseri*, *L. cellobiosis*, *L. brevis*, *L. delbrueckii*, *L. helveticus*, *L. salivarius*, *L. collinoides*, *L. buchneri*, *L. rogosae*, or *L. bifidum*.

18. The method of claim 14 wherein said second probiotic organism is selected from the group consisting of *B. bifidum*, *B. adolescentis*, *B. infantis*, *B. pseudolongum*, *B. angulatum*, *B. catenulatum* or *B. longum*.

19. A method of enhancing protective gastrointestinal flora in newborns comprising administering a therapeutically effective amount of at least one probiotic organism and a pharmaceutically acceptable carrier.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58465 A3

- (51) International Patent Classification⁷: **A61K 35/74**, A61P 1/00 (74) Agents: **ZAHL, Adrian** et al.; McFadden, Fincham, Suite 606, 225 Metcalfe Street, Ottawa, Ontario K2P 1P9 (CA).
- (21) International Application Number: **PCT/CA01/00157** (81) Designated States (*national*): AU, CA, MX.
- (22) International Filing Date: 9 February 2001 (09.02.2001) (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/181,702 10 February 2000 (10.02.2000) US
Published: — with international search report
- (71) Applicants and (88) Date of publication of the international search report:
(72) Inventors: **REID, Gregor** [CA/CA]; 71 Chesham Avenue, 25 April 2002
London, Ontario N6G 3V1 (CA). **BRUCE, Andrew, W.** [CA/CA]; 485 Sandford Road, R.R. #1, Uxbridge, Ontario L9P 1R1 (CA). **HAN, Victor** [CA/CA]; 132 Timber Crescent, London, Ontario N6K 2W2 (CA).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/58465 A3

(54) Title: PROBIOTIC THERAPY FOR NEWBORNS

(57) Abstract: The invention relates to a probiotic microbes including but not limited to *Lactobacillus* species and *Bifidobacteria* species, and their compositions and methods of employing said compositions for treating and preventing intestinal and other infections which originate from the intestine, newborn infants. The invention also relates to the ability of probiotic organisms, either in viable or nonviable state, or their by-products, to interfere with pathogenic infection through short and long term colonization of the intestine, inhibition of growth of the pathogens, and assisting the host to fight off the infecting organisms.

IN TERNATIONAL SEARCH REPORT

Inter. nat. Application No
PCT/CA 01/00157

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K35/74 A61P1/00				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	DATABASE WPI Section Ch, Week 199325 Derwent Publications Ltd., London, GB; Class B04, AN 1993-204155 XP002177145 & SU 1 743 607 A (MOSC SECOND MED INST), 30 June 1992 (1992-06-30) abstract	1-4,6,7, 11-13,19		
X	US 5 922 375 A (TSAI SHU-JEAN ET AL) 13 July 1999 (1999-07-13) the whole document especially column 4 lines 28-33 --- -/---	1,2,13, 19		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.				
<input checked="" type="checkbox"/> Patent family members are listed in annex.				
* Special categories of cited documents :				
<table border="0"> <tr> <td style="vertical-align: top;"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="vertical-align: top;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family			
Date of the actual completion of the international search 10 September 2001		Date of mailing of the international search report 20/09/2001		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl. Fax: (+31-70) 340-3016		Authorized officer Stein, A		

INTERNATIONAL SEARCH REPORT

Inter. Application No

PCT/CA 01/00157

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 984 575 A (FARR STEWART M) 5 October 1976 (1976-10-05) the whole document especially column 1 lines 12-14 and column 2 line 19 ---	1,2,4,5, 7,11-13, 15,19
X	WO 95 33046 A (BOTTAZZI VITTORIO ;HAEN CHRISTOPH DE (IT); DIBRA SPA (IT); BRACCO) 7 December 1995 (1995-12-07) page 5, line 6 -page 6, line 9 page 27, line 2 - line 15 claims 1-12 ---	1,2,4,5, 7,11-13, 15,17,19
X	US 5 902 578 A (HALPIN-DOHNALEK MARGARET IONE ET AL) 11 May 1999 (1999-05-11) the whole document ---	1,2,4,5, 7,11-19
P,X	WO 00 71138 A (REID GREGOR ;BRUCE ANDREW W (CA)) 30 November 2000 (2000-11-30) the whole document especially page 5 lines 1-7 ---	1-19
P,X	US 6 132 710 A (MORRIS JR J GLENN ET AL) 17 October 2000 (2000-10-17) the whole document -----	1,2,4,5, 7,11-15, 17,19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,3-14,19 (all partially)

Present claims 1,3-14 and 19 relate to organisms defined by reference to a desirable characteristic or property, namely their probiotic activity. However these claims do not contain any essential characteristic of the organism and therefore the claims cover all organisms having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such organisms. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the organism by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the organisms mentioned in the description at page 5 lines 5-16, page 5 line 28-page 6 line 2, page 9 line 31-page 11 line 7 and in claims 2 and 15-18. Additionally the general term 'probiotic' has been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 01/00157

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
SU 1743607 A	29-06-1992	NONE	
US 5922375 A	13-07-1999	US 5902743 A	11-05-1999
US 3984575 A	05-10-1976	US 3953609 A	27-04-1976
WO 9533046 A	07-12-1995	IT 1269838 B	15-04-1997
		IT 1274733 B	24-07-1997
		AT 163042 T	15-02-1998
		AU 686389 B	05-02-1998
		AU 2613995 A	21-12-1995
		BR 9507752 A	07-10-1997
		DE 69501591 D	12-03-1998
		DE 69501591 T	10-06-1998
		DE 760848 T	28-08-1997
		DK 760848 T	23-09-1998
		EP 0760848 A	12-03-1997
		ES 2099056 T	16-05-1997
		FI 964681 A	08-01-1997
		GR 97300016 T	31-05-1997
		GR 3026758 T	31-07-1998
		HU 75555 A	28-05-1997
		JP 10500577 T	20-01-1998
		NO 964966 A	23-01-1997
		NZ 287420 A	19-12-1997
		US 5709857 A	20-01-1998
US 5902578 A	11-05-1999	WO 9735596 A	02-10-1997
WO 0071138 A	30-11-2000	AU 4905300 A	12-12-2000
US 6132710 A	17-10-2000	NONE	